Compare Stocks: DTIL, AURA, NVCT, and MNPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.44 -2.3%	$7.32	$4.73 ▼ $9.53	$667.86M	0.4	643,077 shs	3.78 million shs
DTIL Precision BioSciences	$6.67	$7.58	$3.53 ▼ $9.62	$184.11M	1.24	236,763 shs	240,367 shs
MNPR Monopar Therapeutics	$96.47 -6.1%	$111.72	$50.07 ▼ $124.82	$647.53M	1.49	133,432 shs	382,774 shs
NVCT Nuvectis Pharma	$22.00 +2.9%	$21.40	$5.55 ▼ $29.27	$718.17M	-0.26	185,647 shs	880,110 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-7.87%	-17.12%	+1.58%	+5.57%
DTIL Precision BioSciences	0.00%	-6.97%	-23.51%	-2.06%	+47.24%
MNPR Monopar Therapeutics	0.00%	-12.51%	-13.00%	+42.49%	+44.76%
NVCT Nuvectis Pharma	0.00%	-8.30%	-5.78%	+59.19%	+255.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.44 -2.3%	$7.32	$4.73 ▼ $9.53	$667.86M	0.4	643,077 shs	3.78 million shs
DTIL Precision BioSciences	$6.67	$7.58	$3.53 ▼ $9.62	$184.11M	1.24	236,763 shs	240,367 shs
MNPR Monopar Therapeutics	$96.47 -6.1%	$111.72	$50.07 ▼ $124.82	$647.53M	1.49	133,432 shs	382,774 shs
NVCT Nuvectis Pharma	$22.00 +2.9%	$21.40	$5.55 ▼ $29.27	$718.17M	-0.26	185,647 shs	880,110 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-7.87%	-17.12%	+1.58%	+5.57%
DTIL Precision BioSciences	0.00%	-6.97%	-23.51%	-2.06%	+47.24%
MNPR Monopar Therapeutics	0.00%	-12.51%	-13.00%	+42.49%	+44.76%
NVCT Nuvectis Pharma	0.00%	-8.30%	-5.78%	+59.19%	+255.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	2.33	Hold	$17.50	171.74% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	383.51% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$120.08	24.48% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	64.77% Upside

Current Analyst Ratings Breakdown

Latest DTIL, AURA, NVCT, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$128.00 ➝ $145.00
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/20/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	MNPR Monopar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$117.00 ➝ $133.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
DTIL Precision BioSciences	$34.26M	5.37	N/A	N/A	$4.03 per share	1.66
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	11/12/2026 (Estimated)
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)

Latest DTIL, AURA, NVCT, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	16.82	16.82
DTIL Precision BioSciences	0.50	12.82	12.82
MNPR Monopar Therapeutics	N/A	33.56	33.56
NVCT Nuvectis Pharma	N/A	1.68	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
DTIL Precision BioSciences	37.99%
MNPR Monopar Therapeutics	1.83%
NVCT Nuvectis Pharma	96.77%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	1.90%
DTIL Precision BioSciences	2.70%
MNPR Monopar Therapeutics	9.70%
NVCT Nuvectis Pharma	28.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	113	103.71 million	101.74 million	Not Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	No Data
MNPR Monopar Therapeutics	22	6.71 million	6.06 million	Not Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable

DTIL, AURA, NVCT, and MNPR Headlines

Recent News About These Companies

Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest Today

September 18 at 8:31 AM | seekingalpha.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 5.6% - Should You Sell?

September 15, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 6.6% - Still a Buy?

September 11, 2026 | marketbeat.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 9, 2026 | americanbankingnews.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 4, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Upgraded by Lucid Cap Mkts to "Strong-Buy" Rating

September 4, 2026 | marketbeat.com

BlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCT

September 4, 2026 | marketbeat.com

Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)

September 3, 2026 | markets.businessinsider.com

Nuvectis Pharma To Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Alyeska Investment Group L.P. Purchases New Shares in Nuvectis Pharma, Inc. $NVCT

September 2, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 4.2% - Here's Why

September 1, 2026 | marketbeat.com

Stonepine Capital Management LLC Makes New Investment in Nuvectis Pharma, Inc. $NVCT

August 28, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Down 5.2% - Here's What Happened

August 26, 2026 | marketbeat.com

Cantor Fitzgerald Initiates Coverage on Nuvectis Pharma (NASDAQ:NVCT)

August 24, 2026 | marketbeat.com

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

August 19, 2026 | zacks.com

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

August 9, 2026 | theglobeandmail.com

Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next

August 6, 2026 | tipranks.com

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

August 4, 2026 | finance.yahoo.com

Nuvectis Pharma Reports Q2 2026 Results, Highlights In-Licensing of Ciprocopan and NXP200 and $115 Million Follow-On Offering

August 4, 2026 | quiverquant.comQ

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

July 29, 2026 | zacks.com

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement ...

July 23, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DTIL, AURA, NVCT, and MNPR Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.44 -0.15 (-2.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.44 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Precision BioSciences NASDAQ:DTIL

$6.67 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.65 -0.02 (-0.30%)

As of 09/18/2026 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Monopar Therapeutics NASDAQ:MNPR

$96.47 -6.23 (-6.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$96.19 -0.28 (-0.29%)

As of 09/18/2026 07:30 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Nuvectis Pharma NASDAQ:NVCT

$22.00 +0.62 (+2.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.15 +0.15 (+0.66%)

As of 09/18/2026 07:44 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, AURA, NVCT, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, AURA, NVCT, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, AURA, NVCT, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DTIL, AURA, NVCT, and MNPR Company Descriptions

Aura Biosciences NASDAQ:AURA

Precision BioSciences NASDAQ:DTIL

Monopar Therapeutics NASDAQ:MNPR

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, AURA, NVCT, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, AURA, NVCT, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, AURA, NVCT, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DTIL, AURA, NVCT, and MNPR Company Descriptions

Aura Biosciences NASDAQ:AURA

Precision BioSciences NASDAQ:DTIL

Monopar Therapeutics NASDAQ:MNPR

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools